Evidence map›Paper›PMID 34376997›Full record

ArticleOncoTargets and therapy2021

Acquired

Bin Yao, Xue Han, Linrong Pang, Caihong Xu, Sisi Liu, Xiaochun Cheng, Jun Chen

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Efficacy analysis ofJournal of thoracic disease · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bin YaoDepartment of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Xue HanDepartment of Research and Development, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Linrong PangDepartment of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Caihong XuDepartment of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Sisi LiuDepartment of Research and Development, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Xiaochun ChengDepartment of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Jun ChenDepartment of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Ningbo University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic lymphoma kinase (

Indexed as

ALK rearrangementdynamic monitoringnext-generation sequencingresistance mutation

Identifiers

PMID34376997
PMCPMC8349191
OpenAlexW3191431036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.